Answers are grounded in this paper and cite their sources.
• Dual Progestin System (DPS) using LNG-IUS + ESI provides strong pain relief in severe, refractory endometriosis. • Significant reduction in VAS pain scores observed within 3–6 months, sustained long-term. • DPS offers combined local and systemic progestin exposure to overcome partial progesterone resistance. • High continuation rates and only mild, well-tolerated side effects reported. • Represents a promising alternative to repeated surgery and hypoestrogenic GnRH therapies. To evaluate the clinical effectiveness of a dual progestogen-delivery system (DPS) using a levonorgestrel-releasing intrauterine system (LNG-IUS) combined with an etonogestrel subdermal implant (ESI) in women with severe, refractory endometriosis-associated pelvic pain. A retrospective analysis of 105 patients treated with simultaneous LNG-IUS and ESI for durations ranging from 24 to 102 months. Tertiary referral centers and university-affiliated hospitals. Women with surgically confirmed endometriosis and persistent pelvic pain unresponsive to standard care (medical and/or surgical management). Pain relief (measured by VAS), continuation rates, treatment duration, and reported adverse events. The mean treatment duration was 28.1 months. Significant pain reduction was reported in 85% of patients, with VAS scores decreasing from a baseline mean of 9/10 to 3/10 (SD ± 1.04) by 3 months, and to minimal or no pain by 6 months. Most patients (n = 90/105, 85%) sustained symptom relief throughout therapy. Mild adverse effects were reported in 50% of patients, though primarily mild and non-disruptive. The DPS represents a promising, alternative, long-term therapeutic option for managing severe, refractory endometriosis-related pain, offering both uterine and systemic suppression of endometriotic activity.
No takes yet. Share an insight, caveat, or question.
Ng et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: